These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 23225519)

  • 21. Rejection rates in a randomised trial of tacrolimus monotherapy versus triple therapy in liver transplant recipients with hepatitis C virus cirrhosis.
    Samonakis DN; Mela M; Quaglia A; Triantos CK; Thalheimer U; Leandro G; Pesci A; Raimondo ML; Dhillon AP; Rolles K; Davidson BR; Patch DW; Burroughs AK
    Transpl Infect Dis; 2006 Mar; 8(1):3-12. PubMed ID: 16623815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis.
    Jain A; Mazariegos G; Pokharna R; Parizhskaya M; Kashyap R; Kosmach-Park B; Smith A; Fung JJ; Reyes J
    Transplantation; 2003 Apr; 75(7):1020-5. PubMed ID: 12698091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rejection episodes and 3-year graft survival under sirolimus and tacrolimus treatment after adult intestinal transplantation.
    Lauro A; Dazzi A; Ercolani G; Zanfi C; Golfieri L; Amaduzzi A; Cucchetti A; La Barba G; Grazi GL; D'Errico A; Vivarelli M; Cescon M; Varotti G; Del Gaudio M; Ravaioli M; Di Simone M; Faenza S; Pironi L; Pinna AD
    Transplant Proc; 2007 Jun; 39(5):1629-31. PubMed ID: 17580204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liver transplantation using sirolimus and minimal corticosteroids (3-day taper).
    Trotter JF; Wachs M; Bak T; Trouillot T; Stolpman N; Everson GT; Kam I
    Liver Transpl; 2001 Apr; 7(4):343-51. PubMed ID: 11303295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence and outcome of chronic rejection in CyA- and FK 506-treated patients.
    Platz KP; Tullius SG; Mueller AR; Schumacher G; Nüssler N; Neuhaus R; Bechstein WO; Lobeck H; Neuhaus P
    Transplant Proc; 1996 Dec; 28(6):3183-4. PubMed ID: 8962235
    [No Abstract]   [Full Text] [Related]  

  • 26. Recurrent hepatitis C virus hepatitis in liver transplant recipients receiving tacrolimus: association with rejection and increased immunosuppression after transplantation.
    Singh N; Gayowski T; Ndimbie OK; Nedjar S; Wagener MM; Yu VL
    Surgery; 1996 Apr; 119(4):452-6. PubMed ID: 8644012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sirolimus as primary immunosuppressant for calcineurin inhibitor-related renal insufficiency after liver transplantation.
    Yang YJ; Li LX; He Q; Fan H; Jin ZK; Lang R; Kou JT; Li P; Xie DH; Chen DZ
    Hepatobiliary Pancreat Dis Int; 2007 Aug; 6(4):376-8. PubMed ID: 17690032
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapamycin-based rescue therapy after chronic rejection in a pediatric liver transplant patient.
    Iglesias J; Ortega J; López JA; Sánchez L; Allende E; Asensio M; Margarit C
    Transpl Int; 2003 Oct; 16(10):765-7. PubMed ID: 12827229
    [No Abstract]   [Full Text] [Related]  

  • 29. Rejection-free protocol using sirolimus-tacrolimus combination for pediatric renal transplant recipients.
    El-Sabrout R; Weiss R; Butt F; Delaney V; Qadir M; Hanson P; Butt K
    Transplant Proc; 2002 Aug; 34(5):1942-3. PubMed ID: 12176636
    [No Abstract]   [Full Text] [Related]  

  • 30. Tacrolimus (FK506)-based dual versus triple therapy following liver transplantation.
    Samuel D; Bismuth H; Boillot O; Ducerf C; Baulieux J; Gugenheim J; Baldini E; Launois B; Messner M; Wolf P; Ellero E; Domergue J; Pageaux J; Cherqui D; Duvoux C; Durand F; Belghiti J; Calmus Y; Massault PP; Neau-Cransac M; Saric J; LeTreut Y; Campan P
    Transplant Proc; 1998 Jun; 30(4):1394-6. PubMed ID: 9636563
    [No Abstract]   [Full Text] [Related]  

  • 31. Reduced incidence of acute, refractory acute, and chronic rejection after liver transplantation with FK506-based immunosuppression. European FK506 Multicentre Liver Study Group.
    Transplant Proc; 1994 Dec; 26(6):3260-3. PubMed ID: 7527960
    [No Abstract]   [Full Text] [Related]  

  • 32. Immunosuppression and modulation in liver transplantation.
    Encke J; Uhl W; Stremmel W; Sauer P
    Nephrol Dial Transplant; 2004 Jul; 19 Suppl 4():iv22-5. PubMed ID: 15240845
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early tacrolimus exposure after liver transplantation: relationship with moderate/severe acute rejection and long-term outcome.
    Rodríguez-Perálvarez M; Germani G; Papastergiou V; Tsochatzis E; Thalassinos E; Luong TV; Rolando N; Dhillon AP; Patch D; O'Beirne J; Thorburn D; Burroughs AK
    J Hepatol; 2013 Feb; 58(2):262-70. PubMed ID: 23023010
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: experience in a single center.
    Testillano M; Fernandez JR; Suarez MJ; Gastaca M; Bustamante J; Pijoan JI; Montejo M; Valdivieso A; Ruiz P; Gonzalez J; Ortiz de Urbina J
    Transplant Proc; 2009 Apr; 41(3):1041-3. PubMed ID: 19376421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of African-American kidney-transplant recipients treated with sirolimus, tacrolimus, and corticosteroids.
    Egidi MF; Gaber AO
    Transplantation; 2003 Feb; 75(4):572; author reply 573. PubMed ID: 12605133
    [No Abstract]   [Full Text] [Related]  

  • 36. A cyclosporine-based immunosuppressive regimen may be better than tacrolimus for long-term liver allograft survival in recipients transplanted for hepatitis C.
    Rayhill SC; Barbeito R; Katz D; Voigt M; Labrecque D; Kirby P; Miller R; Stolpen A; Wu Y; Schmidt W
    Transplant Proc; 2006 Dec; 38(10):3625-8. PubMed ID: 17175350
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Basiliximab induction in adult liver transplant recipients with 93% rejection-free patient and graft survival at 24 months.
    Ramirez CB; Doria C; di Francesco F; Iaria M; Kang Y; Marino IR
    Transplant Proc; 2006 Dec; 38(10):3633-5. PubMed ID: 17175352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post-liver transplantation immunosuppression: the song does not remain the same.
    Yoshida EM
    Can J Gastroenterol; 2002 Jan; 16(1):65-6. PubMed ID: 11826341
    [No Abstract]   [Full Text] [Related]  

  • 39. Alemtuzumab preconditioning allows steroid-calcineurin inhibitor-free regimen in live-donor kidney transplant.
    Refaie AF; Mahmoud KM; Ismail AM; Sheashaa HA; Kamal AI; Ghoneim MA
    Exp Clin Transplant; 2011 Oct; 9(5):295-301. PubMed ID: 21967254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preliminary immunosuppression withdrawal strategies with sirolimus in children with liver transplants.
    Sindhi R; Ganjoo J; McGhee W; Mazariegos G; Reyes J
    Transplant Proc; 2002 Aug; 34(5):1972-3. PubMed ID: 12176651
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.